Don't invest unless you're prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.
Osstec was founded to address the growing prevalence of knee osteoarthritis (1.3m people are currently affected globally) and the high long term failure rate of the solutions currently available. 35% of existing knee implants fail, primarily as a result of loosening between the implant and the bone.
The expectations of the capacity of implants varies considerably with age group: elderly patients tend to emphasise pain reduction and restoring mobility, while younger patients emphasise the need for implants resilient enough to facilitate a return to an active lifestyle. Implants that can cover all demand levels are ideal.
A further complication with many existing implants is the use of bone cement, which has been found to be a contributor to implant failure as well as to other complications and side effects. Cementless implants have been found to fail 50% less.
Osstec’s solution is an additive manufacturing bone healing technology, currently applied in partial knee implants, that represents a new generation of implant. Its fully 3D printed lattice mimics the porous structure of bone, allowing natural load transfer through the knee that diminishes the negative effect of stress shielding.
This implant solution stimulates long-term bone growth to resolve common sources of failure: loosening and bone loss. Its vision is to keep patients active, pain-free and enjoying added years of improved quality of life.
“A younger patient has about a 35% chance of implant failure during their lifetime, and the leading cause of failure is loss of fixation between the bone and the implant,” Dr Max Munford, Co-founder and Chief Executive of Osstec said in an interview for Imperial College’s news site. “New technologies mean we can do much more for younger patients and provide a much more innovative solution than the existing, solid metal implants, and that is what we are doing here at Osstec.”
Since the Access EIS Fund invested in Osstec in 2023, its share price has increased by 200%.
Key milestones
2023 - Growth of IP portfolio - 5 patents spanning global markets
March 2023 - Access EIS invests
2023 - Raised £1.2m seed round
2022 - Innovate UK Grant
July 2021 - Osstec founded
What return would investors see on an Osstec exit?
The impressive growth of Osstec has translated into impressive potential returns for early investors. For example, an individual who invested £5,000 in Osstec in 2023 would see their investment valued at £15,012 today if the company were to exit.
Because it is an EIS investment, you would also have been able to:
Claim 30% of your investment as income tax relief (£1,500).
Defer up to £5,000 (the amount invested) of any capital gain arising one year before, and up to three years after, the date of your share acquisition.
Sell your EIS shares free of capital gains tax.
Exempt your EIS shares from your taxable estate. EIS shares qualify for Business Relief.
Invest in companies like Osstec with Access EIS
Osstech is part of Cambridge-based investment fund SyndicateRoom’s [Access EIS Fund]( /access-eis) portfolio, which specialises in backing high-growth startups in the UK. Its approach emphasises co-investing with angel investors and building large portfolios to optimise growth potential and minimise risk.Osstec is one of a number of companies in the Access portfolio seeing growth exceeding 200%.
Find out more about SyndicateRoom
Invest in companies like Osstec with Access EIS
The Access EIS Fund employs a unique model to gain access to some of the most promising new startups in the UK.
By co-investing with carefully vetted angel investors who have demonstrated their expertise in making profitable investments, we are able to back the UK’s best companies earlier in their lifecycle, and win greater potential return multiples for our investors.
We build large, diverse portfolios to optimise growth potential and minimise risk. Investing in startups is risky, and many fail. But with a broad holding of top quality businesses, your chance of investing in one of the UK’s next success stories is increased.
Jove is one of a number of companies in the Access portfolio seeing growth exceeding 200%. We invest in new companies each month, so the sooner you make your investment, the sooner you can start building your portfolio of promising new startups.
Find out more about investing in the Access EIS Fund.
